Nhà máy Stada

Clindastad 150

Pack size:

Box of 5 blisters x 10 capsules.



Each capsule contains clindamycin (as clindamycin hydrochloride) 150 mg.



48 months from the date of manufacturing.

Store in a well-closed container, in a dry place. Do not store above 30oC.


  • Indications and Dosage & Administration
  • Contraindications
  • Adverse reactions
  • Precautions

Because clindamycin has a high risk of causing pseudomembranous colitis (see adverse and side effects), clindamycin is therefore never the first drug of choice.
This drug should be reserved for treatment of infections caused by clindamycin sensitive organisms such as Bacteroides fragilis and Staphylococcus aureus, and particularly in patients who are allergic against penicillin.
Clindamycin is used in following conditions:

  • Prevention of endocarditis or infection due to surgical implant in patients who are allergic to penicillin or in patients who have been on long-term penicillin treatment.
  • Lung abscess, severe respiratory tract infections caused by anaerobes, Streptococci, Staphylococci and Pneumococci.
  • Intra-abdominal infections such as peritonitis and intra-abdominal abscess.
  • Suppurative wound infections (surgical or traumatic).
  • Septicemia.
  • Puerperal fever (genital tract), severe infections of female pelvic and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection caused by anaerobes.

Clindastad 150 is administered orally. The capsule should be always taken with a full glass of water.

  • Adults: 150 to 300 mg of clindamycin every 6 hours; in severe infections, the dose may be increased to 450 mg every 6 hours.
  • Children: 3 to 6 mg/kg, every 6 hours. Those under one year old or weighing 10 kg or less should receive at least 37.5 mg every 8 hours; the oral solution may be appropriated.
  • Prevention of endocarditis or infection due to surgical implant: Clindamycin 600 mg (10 mg/kg for adult dose) orally 1 – 2 hours before surgical procedure, followed by 300 mg (5 mg/kg) orally 6 hours after surgical procedure.
  • Puerperal fever (genital tract): For the women who are febrile but not clinically ill, suitable empirical treatment is amoxicillin + clavulanic acid, but if fever persists for longer 48 hours, clindamycin 300 mg orally, every 8 hours (if there is Mycoplasma) until fever resolved or erythromycin 500 mg orally (if there is Ureaplasma).

Or as prescribed by physicians.


  • Patients previously found to be sensitive to clindamycin, lincomycin or to any ingredient of the drug.


Clindamycin has a high risk of causing pseudomembranous colitis due to a toxin effect from overgrowth of Clostridium difficile. This happens when the normal bacteria of intestinal tract are destroyed by clindamycin (particularly in elderly patients and patients with reduced renal function).
In some patients (0.1 to 10%) very severe pseudomembranous colitis may develop, which may be deadly. This condition is characterized by abdominal pain, diarrhoea, fever, mucus and blood in the stools. Proctoscopic examination reveals white to yellow plaques on the mucosa of colon.
Gastrointestinal adverse effects are seen among approximately 8% of patients.


  • Nausea, vomiting and diarrhoea caused by Clostridium difficile.


  • Urticaria.
  • Local reactions after intramuscular injection, thrombophlebitis after intravenous injection.


  • Anaphylaxis.
  • Eosinophilia and reversible neutropenia.
  • Pseudomembraneous colitis, esophagitis.
  • Reversible liver transaminase elevation.


  • Clindamycin should be used with caution in patients with a history of gastrointestinal disease, particularly colitis, and stopped immediately if significant diarrhoea or colitis occurs. Middle-aged and elderly female patients may be at greater risk of severe diarrhoea or pseudomembranous colitis.
  • Caution has also been advised in atopic patients.
  • Periodic tests of liver and kidney function and blood counts have been recommended in patients receiving prolonged therapy, and in infants.
  • Caution in patients with a history of colitis.
  • Dosage adjustment is recommended and periodic liver enzymes tests should be carried out in patients with severe hepatic impairment.
  • Clindamycin should be used during pregnancy only when clearly needed.
  • Clindamycin is excreted in breast milk (about 0.7 to 3.8 micrograms/ml), so breast feeding should be avoided during therapy of drug.
  • The effect of clindamycin on the ability to drive or operate machinery has not been systemically evaluated.


Contact us

FACTORY 1: K63/1 Nguyen Thi Soc St., Xuan Thoi Dong, Hoc Mon, HCMC
Tel: +84 28 3718 2141 - Fax: +84 28 3718 2140

FACTORY 2: 40 Tu Do Avenue, VietNam-Singapore Industrial Park, Binh Duong
Tel: +84 274 376 7470 - Fax: +84 274 376 7469
Email : stada@stada.com.vn
Website: www.stada.com.vn

Visitors Counter